Compare KALV & TIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KALV | TIPT |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.7M | 653.2M |
| IPO Year | 2014 | 2017 |
| Metric | KALV | TIPT |
|---|---|---|
| Price | $17.04 | $15.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 761.7K | 235.6K |
| Earning Date | 05-09-2026 | 03-06-2026 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | ★ $50,000,000.00 | $488,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.68 |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $15.59 |
| 52 Week High | $19.00 | $27.38 |
| Indicator | KALV | TIPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 33.14 |
| Support Level | $14.59 | N/A |
| Resistance Level | $17.30 | $18.39 |
| Average True Range (ATR) | 1.10 | 0.44 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 53.88 | 11.35 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.